{"name":"ICON plc","slug":"icon","ticker":"ICLR","exchange":"NASDAQ","domain":"iconplc.com","description":"ICON plc is an Irish headquartered multinational healthcare intelligence and clinical research organisation. As of February 2025 had approximately 41,900 employees in 55 countries.","hq":"Dublin, Ireland","founded":1969,"employees":"39800","ceo":"Steve Cutler","sector":"Contract Research Organization (CRO)","stockPrice":121.68,"stockChange":4.3,"stockChangePercent":3.66,"marketCap":"$9.5B","metrics":{"revenue":8102602240,"revenueGrowth":0.6,"grossMargin":28.2,"rdSpend":0,"netIncome":791474000,"cash":538785000,"dividendYield":0,"peRatio":16.4,"fiscalYear":"FY2013"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-06-01","label":"Lipitor patent cliff ($1.4B at risk)","drug":"Lipitor","type":"patent_expiry","sentiment":"negative"},{"date":"2020-06-01","label":"Viagra patent cliff ($0 at risk)","drug":"Viagra","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-22","type":"earnings","headline":"ICON plc Reports Fourth Quarter and Full Year 2023 Results","summary":"ICON plc reported its fourth quarter and full year 2023 results, with revenue of $2.4 billion and adjusted diluted earnings per share of $1.93.","drugName":"","sentiment":"positive"},{"date":"2023-11-01","type":"deal","headline":"ICON plc Announces Acquisition of PPD's Clinical Research Unit","summary":"ICON plc announced the acquisition of PPD's clinical research unit, expanding its capabilities in clinical development.","drugName":"","sentiment":"positive"},{"date":"2023-08-31","type":"regulatory","headline":"FDA Approves ICON plc's Clinical Trial Management System","summary":"The FDA approved ICON plc's clinical trial management system, a key milestone in the company's commitment to innovation.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQOVNCZXExTzlIR0dYVzZEXzM1Z0RUSnc2NnhIc1RHQXBZX0FsTjNfX3prdkNsdnpxRUNTem1YTFpndG9Pb2hNcFRoUlJjM19EeW1tVjdDeE5rZHZwVnJvVmFCMXdDWnRlYTJ0NGs4QVpxcHFkYUt3SnZrREhrSG1PWXgtN1I3cTJLRUlpQWhjbDZhUjJGakJIbW5xVnA5T3RsVml4Z1I4UTAxZHpwYTZGRTBzX3l0dUhoTTJ3WTF3?oc=5","date":"2026-03-26","type":"pipeline","source":"Investing.com","summary":"BMO upgrades ICON stock rating on pharma backdrop improvement - Investing.com","headline":"BMO upgrades ICON stock rating on pharma backdrop improvement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNa0F4bEJlUndOZ2NfbXJVS2RiakxaTktPZWZCYkQtLS1pY0Q2NGFkeG9xa0dBM0hxMEhaR0JLdHBLSi1oUjlhZEdBMnhZUFJIek93QkVwUzFBNzBzU0FtbkZoQTV0RzRCTWxUWFJlWnduVjEtU0Q2dFhUeFJYSTFVWHZ6TklIRXJsaUVKVFZ5ckJIcEt4Y1g3blJqOGxuWFZUTDdkSm4wRmxGT1pxcHlVQU1UdkQtRXpubm8yaV8xVUlQQQ?oc=5","date":"2026-03-12","type":"pipeline","source":"MarketBeat","summary":"Franklin Resources Inc. Purchases 719,301 Shares of Icon Plc $ICLR - MarketBeat","headline":"Franklin Resources Inc. Purchases 719,301 Shares of Icon Plc $ICLR","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxOcEVNdFI4ZUN2alpWSkplQ3FUN1JqdndxWk1YblNMZ3FObllsa0xXNFA0XzBzMWxHbTdoclhsaU9xV1piVXpGZmxMNWxPNi1hUDgxanNlZS1tZ2RmaENTbk5DSmw0SnlFV2tGc3ZYRWV6Z25vNHpxSWE1YTRCQjVkY3pseVRqZGtCX25oaXZudlpmc0VNcl9kN3pIeHZqOUZWWk90Sm5KQ3AxYllGbFFObmpYNzloVVJoS2VYUkdRdUhvOG9JQ2VFSlUwN3poYUxpcTdaYnR3ZWlqNi1OS2g0?oc=5","date":"2026-02-18","type":"earnings","source":"PR Newswire","summary":"ICON plc Faces Investigation After Internal Probe Reveals Multi-Year Revenue Overstatement - PR Newswire","headline":"ICON plc Faces Investigation After Internal Probe Reveals Multi-Year Revenue Overstatement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxOZ0JUUEd2R0czd0ZkOHJlUFVaWXpxUzI1TVk4SHR0SUZFSGh0VmxKYThRZFhxMWF1NW84Q2J6ZE94Yl9JRHdFMF85Qno3ZlNKX2RwQWhCZkxkeGM0OHlsV2NBY2lLY0ZuVTI1bVNmVl8zLUVSaXdQTTVFQl8zMWdHbUJrcTI5dGlkYmVyRHRpTDM5ZlN6b1NzUGdlaGZiTHRlTmRpWDBzRk96cmY2UTNTTHVwRWx4YWs2OHJjZlF0M1dOam1lYWxHTFFzejNrRTFoa1E1Vkt6NDZSaGc2dkMtOHlyYmVzS3Bv?oc=5","date":"2026-02-12","type":"pipeline","source":"FinancialContent","summary":"The Clinical Crisis: A Deep-Dive Into ICON plc (ICLR) Amidst a Transformational Storm - FinancialContent","headline":"The Clinical Crisis: A Deep-Dive Into ICON plc (ICLR) Amidst a Transformational Storm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE1PZmY0NmV5TWxhVGlJczdmWVlOTVY5ZzJMMktOc3Z4TlB4bzdsbjVWbDJsNjhIbUNERXN1cnpMbWJ5bmJIMmMzSF9vcDU0XzdYNXJNcF9TMkZiRW1SU1HSAWNBVV95cUxQbnptV0dvVEZHTWR2SlphT290MUg3OTI1VldKc3B5VXJCQVhkTjE5V3N0M3RJeWlDUDZOdDNFeUFjckJRZUJzQXRvVl9kSWNXSmUwd2pYZjJ1YS04QjYyUzdHUG8?oc=5","date":"2026-02-12","type":"pipeline","source":"Bitget","summary":"Clinical Research Provider Icon Stock Crashes On Accounting Probe - Bitget","headline":"Clinical Research Provider Icon Stock Crashes On Accounting Probe","sentiment":"neutral"},{"date":"2026-02-12","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE5WZkRfUzhFN3kyT3RmUWhaWFJpMFJVNnpmWGJkRTFlMXpOTldyX3o3b25vVzRUUkdkazVUQlB5QW85ZS1iOHpSeURRMGlwbGlDV191WTJiTXBNM2VhY1hsMXEzREIzT2FsQlBIN1ZSZXZUV1dQYnMyZVF4bWM?oc=5","date":"2026-01-21","type":"earnings","source":"Yahoo Finance","summary":"ICON PLC (ICLR) Trades Below Normal Earnings Despite Strong Fundamentals - Yahoo Finance","headline":"ICON PLC (ICLR) Trades Below Normal Earnings Despite Strong Fundamentals","sentiment":"positive"},{"date":"2026-01-07","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPMnJGN01KS2tWVXdhQjdXZUhldjEzb1dNbVNfOGJqTlNrRWxDcU94OEEzQWN2WjBoWmJOUHJJcVp1bnRWTnhfRmIzM1k5NWtZTUdHeWVLd0E0RHJWXy1FZm1kZTlsMlZKVDlVWlUxT19VTjVubmNMRUxlb3B5NWZJNXppSlhkLVZETXFlaE82OGVRbVFXTEo2UnFvQVFlQk55SDQycWhLRl9hMjNQQVdPSUhRNjB3Rnc?oc=5","date":"2026-01-04","type":"pipeline","source":"AD HOC NEWS","summary":"ICON plc Is Quietly Eating Wall Street: Is ICLR the Undervalued Game-Changer No One On TikTok Knows - AD HOC NEWS","headline":"ICON plc Is Quietly Eating Wall Street: Is ICLR the Undervalued Game-Changer No One On TikTok Knows","sentiment":"neutral"},{"date":"2025-11-12","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-09","type":"pipeline","source":"simplywall.st","summary":"ICON plc (ICLR): Assessing Valuation as CEO Transition Confirms Stability and 2025 Guidance - simplywall.st","headline":"ICON plc (ICLR): Assessing Valuation as CEO Transition Confirms Stability and 2025 Guidance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQTUNZc0dsdVBxeTNNRVRxX29nY1B4ZWZNRkhuTElyNGJxZDVqdFhKcUl1TDdYd2FNeXdFX0JGeFY4Wm5QMXlmUkN5MTUxVU5RcXgxbExPVHlDMDE0ZFVYeE9ZZ1VySjNTMHFCUy1aNURqR05TaDhvUFY5LTI0Q1hXd3JROXhtajdrM1g0M3kzQQ?oc=5","date":"2025-09-04","type":"pipeline","source":"Business Wire","summary":"ICON Announces CEO Transition - Business Wire","headline":"ICON Announces CEO Transition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOTWRNb0hURk5xVHdMSU45alMxN01IaHcxb21GOGFPbnFyWF9lVDNEYnhZMTRDaHdJMGlTc2ZIVUJyelJCa1g5WWd6TlFqSjdiQ20zZUV2cWV1aE1pTU5IOTF2b1BHODdIVExuZ1h1bDN4WTBaS3ZyY1BmME9rclhmMW5KMUFjb1JEVkg4LUFGaG5LZXRLTHc2eTllTW1Ja3BUQ1FyN0tCcmNqV0c4MlNmRG1jaHZCdTRXZG90UFBGOWQ?oc=5","date":"2025-07-24","type":"regulatory","source":"Barron's","summary":"S&P 500 Futures Climb in Premarket Trading; West Pharmaceutical Svcs, Icon PLC Lead - Barron's","headline":"S&P 500 Futures Climb in Premarket Trading; West Pharmaceutical Svcs, Icon PLC Lead - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigJBVV95cUxOQU1JRG44ZjEtTFR6Qk55WkpsbWdtWGxrZ3RlRXBjVFpCSnNuWHNvR2p2dGNMQmV5dnpNTlJIaG1aSTUzTjE2VWg5YzZOZlp5MkZmSHlWRzQxU1Y5U0hIQ0NJcFJ6Y2FhaDlaNmRlZWV0TkxobmZsbjZjcFdYR2tKN0xObi1STmlmX0R6RmVvcFVvazJBcllraHhvZVVmbkk3OGdxS05RcVI2c3pxNHljbjhPdjVmcUgxN3VWUlUzYkRRRmVqdXNaNm9XTXJUWnhUUk0wQ2daYjVUWE1aM3dZTHhNMnhOa1ZDUXNNUlhDeVpEc3FTQzVvWjZZbWNNVVVrMkY0XzNQMnhuUQ?oc=5","date":"2025-07-07","type":"pipeline","source":"Business Wire","summary":"ICON and Its Employees Recognised as Clinical Research Industry Leaders, and for Innovation and Progress in Sustainability - Business Wire","headline":"ICON and Its Employees Recognised as Clinical Research Industry Leaders, and for Innovation and Progress in Sustainabili","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1hbTFKYktjLS1EQ0NkS3A5czhhSkptSDNWQ1l5U0pzZkxQbWM3cERfeTNnT3M5RWRxZXpXNkpLZ2Z2T1kyeDNVaHVTM2NuU21KLTg0?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"ICLR Stock Price, News & Analysis | ICON - Stock Titan","headline":"ICLR Stock Price, News & Analysis | ICON","sentiment":"neutral"}],"patents":[{"drugName":"Viagra","drugSlug":"sildenafil","patentNumber":"","type":"Patent Cliff","expiryDate":"2020-06-01","territory":"US","annualRevenue":0},{"drugName":"Lipitor","drugSlug":"atorvastatin","patentNumber":"","type":"Patent Cliff","expiryDate":"2027-06-01","territory":"US","annualRevenue":1400000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["IQVIA","Parexel","Labcorp"],"therapeuticFocus":["Oncology","Cardiovascular","Infectious Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":1336058000,"revenuePeriod":"2013-12-31","revenueHistory":[{"value":1336058000,"period":"2013-12-31"},{"value":1115006000,"period":"2012-12-31"},{"value":945729000,"period":"2011-12-31"},{"value":900044000,"period":"2010-12-31"},{"value":887612000,"period":"2009-12-31"}],"grossProfit":2436357000,"grossProfitHistory":[{"period":"2024-12-31","value":2436357000},{"period":"2023-12-31","value":2400227000},{"period":"2022-12-31","value":2214341000},{"period":"2021-12-31","value":1508214000}],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":728348000,"operatingIncome":1219509000,"operatingIncomeHistory":[{"period":"2024-12-31","value":1219509000},{"period":"2023-12-31","value":1045718000},{"period":"2022-12-31","value":866075000},{"period":"2021-12-31","value":607897000}],"netIncome":791474000,"netIncomeHistory":[{"period":"2024-12-31","value":791474000},{"period":"2023-12-31","value":612335000},{"period":"2022-12-31","value":505304000},{"period":"2021-12-31","value":153185000}],"eps":9.53,"epsHistory":[{"period":"2024-12-31","value":9.53},{"period":"2023-12-31","value":7.4},{"period":"2022-12-31","value":6.13},{"period":"2021-12-31","value":2.25}],"cash":538785000,"cashHistory":[{"period":"2024-12-31","value":538785000},{"period":"2023-12-31","value":378102000},{"period":"2022-12-31","value":288768000},{"period":"2021-12-31","value":752213000}],"totalAssets":16877678000,"totalLiabilities":7354679000,"totalDebt":3603028000,"equity":9522999000,"operatingCashflow":1286652000,"operatingCashflowHistory":[{"period":"2024-12-31","value":1286652000},{"period":"2023-12-31","value":1161027000},{"period":"2022-12-31","value":563315000},{"period":"2021-12-31","value":829142000}],"capex":-168060000,"capexHistory":[{"period":"2024-12-31","value":-168060000},{"period":"2023-12-31","value":-140692000},{"period":"2022-12-31","value":-142160000},{"period":"2021-12-31","value":-93750000}],"freeCashflow":1118592000,"dividendsPaid":null,"buybacks":-499998000,"employees":39800,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":197049000,"ebit":88345000,"ebitda":186840000,"period":"2025-09-30","revenue":2042812000,"epsBasic":0.03,"netIncome":2355000,"rdExpense":null,"epsDiluted":0.03,"grossProfit":554448000,"operatingIncome":258904000},{"sga":205006000,"ebit":211262000,"ebitda":308980000,"period":"2025-06-30","revenue":2017357000,"epsBasic":2.31,"netIncome":182972000,"rdExpense":null,"epsDiluted":2.3,"grossProfit":561599000,"operatingIncome":258875000},{"sga":198384000,"ebit":221363000,"ebitda":317321000,"period":"2025-03-31","revenue":2001332000,"epsBasic":1.91,"netIncome":154151000,"rdExpense":null,"epsDiluted":1.9,"grossProfit":558653000,"operatingIncome":264311000},{"sga":151445000,"ebit":268993000,"ebitda":365648000,"period":"2024-12-31","revenue":2041101000,"epsBasic":3.18,"netIncome":259998000,"rdExpense":null,"epsDiluted":3.16,"grossProfit":599365000,"operatingIncome":351265000},{"sga":205095000,"ebit":287868000,"ebitda":380897000,"period":"2024-09-30","revenue":2030030000,"epsBasic":2.38,"netIncome":197128000,"rdExpense":null,"epsDiluted":2.36,"grossProfit":591414000,"operatingIncome":293290000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":121.68,"previousClose":117.38,"fiftyTwoWeekHigh":211,"fiftyTwoWeekLow":66.57,"fiftyTwoWeekRange":"66.57 - 211.0","fiftyDayAverage":109.47,"twoHundredDayAverage":154.4,"beta":1.23,"enterpriseValue":12065760256,"forwardPE":10.6,"priceToBook":1,"priceToSales":1.17,"enterpriseToRevenue":1.49,"enterpriseToEbitda":7.93,"pegRatio":20.66,"ebitda":1522180992,"ebitdaMargin":18.8,"freeCashflow":925353856,"operatingCashflow":1140356992,"totalDebt":3571518976,"debtToEquity":38.3,"currentRatio":1.06,"returnOnAssets":4.2,"returnOnEquity":6.3,"analystRating":"2.1 - Buy","recommendationKey":"buy","numberOfAnalysts":14,"targetMeanPrice":137.21,"targetHighPrice":180,"targetLowPrice":90,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.7,"institutionHeldPercent":100.5,"sharesOutstanding":76359932,"floatShares":75947588,"sharesShort":2678541,"shortRatio":2.02,"shortPercentOfFloat":3.5,"epsTrailing":7.42,"epsForward":11.47,"revenuePerShare":101.61,"bookValue":122.25,"officers":[{"age":72,"name":"Dr. John  Climax Ph.D.","title":"Founder & Independent Non-Executive Director"},{"age":51,"name":"Mr. Nigel  Clerkin A.C.A.","title":"Chief Financial Officer"},{"age":46,"name":"Mr. Barry  Balfe","title":"CEO & Director"},{"age":null,"name":"Lyons  Emer","title":"Chief Accounting Officer"},{"age":null,"name":"Mr. Thomas N. O'Leary","title":"Chief Information Officer"},{"age":50,"name":"Mr. Diarmaid  Cunningham","title":"Chief Administrative Officer, General Counsel & Company Secretary"},{"age":null,"name":"Ms. Niamh  Murphy","title":"Director of Corporate Communications"},{"age":null,"name":"Mr. David  Green","title":"Vice President of Marketing"}],"industry":"Diagnostics & Research","irWebsite":"","website":"https://www.iconplc.com","phone":"353 1 291 2000"}}